{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.01","upperLimit":"452.22","value":"155.75"}]}],"title":"VEGF Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"70.10","upperLimit":"470.38","value":"209.92"}]}],"title":"VEGF Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"651.8","upperLimit":"15576.39","value":"9594.04"}]}],"title":"VEGF-R2 Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5569.73","upperLimit":"11637.18","value":"7948.48"}]}],"title":"VEG-R2 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Serum VEGF and VEGF receptor 2 Concentration is evaluated at baseline and at day 15 of protocol therapy in picograms/ml.","dispersionType":"Full Range","groups":[{"id":"OG000","title":"Rhabdomyosarcoma and Wilms Tumor"}],"paramType":"MEAN","populationDescription":"Change in VEGF and VEGFR-2 are the responses of the patient's organs to the drug. As such, these measures are unrelated to the particular disease with which the patient was diagnosed, and were combined for analysis.","reportingStatus":"POSTED","timeFrame":"Prior to the administration of sorafenib (baseline) and day 15 of protocol therapy","title":"Change in VEGF and VEGFR-2","type":"SECONDARY","unitOfMeasure":"picograms/ml"}